Annovis Appoints Mark Guerin as Chief Financial Officer
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on neurodegenerative diseases, has appointed Mark Guerin as Chief Financial Officer. Guerin brings significant biopharma financial leadership experience, notably serving as CFO at Onconova Therapeutics (now Traws Pharma) where he managed multiple financing transactions.
The appointment comes at a crucial time as Annovis's lead drug candidate buntanetap advances through late-stage clinical development for Alzheimer's and Parkinson's disease. Guerin's extensive background includes roles at Cardiokine and Barrier Therapeutics, where he oversaw key financial operations including IPOs and corporate transactions.
[ "Appointment of experienced CFO with strong track record in biopharma financing", "Lead drug buntanetap showing promise in late-stage clinical development", "Strategic timing of CFO appointment ahead of potential commercialization phase" ]Annovis Bio (NYSE: ANVS), una azienda di piattaforma di farmaci in fase avanzata focalizzata sulle malattie neurodegenerative, ha nominato Mark Guerin come Chief Financial Officer. Guerin porta una significativa esperienza di leadership finanziaria nel biopharma, avendo ricoperto il ruolo di CFO presso Onconova Therapeutics (ora Traws Pharma), dove ha gestito diverse operazioni di finanziamento. L’appuntamento arriva in un momento cruciale poiché il candidato principale buntanetap avanza nello sviluppo clinico avanzato per Alzheimer e Parkinson. Guerin vanta una vasta esperienza, tra cui ruoli in Cardiokine e Barrier Therapeutics, dove ha supervisionato operazioni finanziarie chiave, tra cui IPO e transazioni aziendali.
Annovis Bio (NYSE: ANVS), una empresa de plataforma de fármacos en fase avanzada centrada en enfermedades neurodegenerativas, ha nombrado a Mark Guerin como Director Ejecutivo de Finanzas. Guerin aporta una amplia experiencia en liderazgo financiero en biopharma, destacando su desempeño como CFO en Onconova Therapeutics (ahora Traws Pharma) donde gestionó múltiples operaciones de financiación. El nombramiento llega en un momento crucial, ya que el candidato principal buntanetap avanza en el desarrollo clínico avanzado para Alzheimer y Parkinson. La experiencia de Guerin incluye cargos en Cardiokine y Barrier Therapeutics, donde supervisó operaciones financieras clave, incluidas IPO y transacciones corporativas.
Annovis Bio (NYSE: ANVS), 말기 임상 약물 플랫폼 회사로 신경퇴행성 질환에 집중, Mark Guerin을 최고재무책임자(CFO)로 임명했습니다. Guerin은 바이오제약 재무 리더십 분야에서 상당한 경력을 보유하고 있으며, 특히 Onconova Therapeutics(현재 Traws Pharma)에서 CFO로 재직하며 여러 자금 조달 거래를 관리했습니다. 이번 임명은 주력 후보물질 buntanetap이 알츠하이머병 및 파킨슨병에 대한 후기 단계 임상 개발에서 진전을 보이고 있는 시점에 이루어졌습니다. Guerin의 광범위한 경력에는 Cardiokine와 Barrier Therapeutics에서 IPO 및 기업 거래를 포함한 주요 재무 운영을 감독한 경험이 포함됩니다.
Annovis Bio (NYSE: ANVS), une société de plateforme pharmaceutique en phase avancée axée sur les maladies neurodégénératives, a nommé Mark Guerin au poste de directeur financier (CFO). Guerin apporte une expérience significative en leadership financier dans le biopharmaceutique, notamment en tant que CFO chez Onconova Therapeutics (désormais Traws Pharma), où il a géré plusieurs opérations de financement. Cette nomination intervient à un moment crucial alors que le candidat principal buntanetap progresse dans le développement clinique avancé pour la maladie d’Alzheimer et la maladie de Parkinson. L’expérience de Guerin inclut des postes chez Cardiokine et Barrier Therapeutics, où il a supervisé des opérations financières clés, y compris des IPO et des transactions d’entreprise.
Annovis Bio (NYSE: ANVS), ein späte Phase klinisches Arzneimittelplattform-Unternehmen mit Fokus auf neurodegenerative Erkrankungen, hat Mark Guerin zum Chief Financial Officer ernannt. Guerin bringt bedeutende Erfahrungen in der biopharmazeutischen Finanzführung mit, insbesondere als CFO bei Onconova Therapeutics (jetzt Traws Pharma), wo er mehrere Finanztransaktionen leitete. Die Ernennung kommt zu einem entscheidenden Zeitpunkt, da der führende Arzneimittelkandidat buntanetap durch die späte klinische Entwicklung für Alzheimer und Parkinson voranschreitet. Guerins umfangreiche Erfahrung umfasst Positionen bei Cardiokine und Barrier Therapeutics, wo er die wichtigsten finanziellen Operationen, einschließlich IPOs und Unternehmenstransaktionen, überwacht hat.
شركة Annovis Bio (بورصة نيويورك: ANVS)، وهي منصة دوائية في مرحلة متأخرة تركز على أمراض الجهاز العصبي التنكسي، قد عيّنت Mark Guerin كمدير مالي رئيسي (CFO). يجلب Guerin خبرة قيادية كبيرة في التمويل في مجال الأدوية الحيوية، لا سيما كونه CFO في Onconova Therapeutics (المعروفة حالياً بـ Traws Pharma)، حيث أدار عدة صفقات تمويل. يأتي التعيين في وقت حاسم بينما يتقدم المرشح العلاجي الرئيس buntanetap في التطوير السريري المتقدم لمرض الزهايمر ومرض باركنسون. تشمل خلفية Guerin خبرات في Cardiokine وBarrier Therapeutics، حيث أشرف على عمليات مالية رئيسية بما في ذلك الطروحات الأولية وعمليات الدمج والاستحواذ.
Annovis Bio（NYSE: ANVS），一家具备晚期临床药物平台的神经退行性疾病专注公司，已任命 Mark Guerin 为首席财务官（CFO）。Guerin 拥有丰富的生物药业财务领导经验，曾任 Onconova Therapeutics（现为 Traws Pharma）CFO，在那里他负责管理多笔融资交易。此次任命正值关键时期，因为公司主导药物候选物 buntanetap 正在推进晚期临床开发，覆盖阿尔茨海默病和帕金森病。Guerin 的广泛背景还包括在 Cardiokine 与 Barrier Therapeutics 担任要职，监督包括首次公开募股（IPO）和企业交易在内的关键财务运作。
- None.
- Company will need significant financing for late-stage clinical trials
- Success of buntanetap in larger trials still needs to be proven
MALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer (CFO) to help lead the Company through a pivotal phase as buntanetap continues to show promise in late-stage clinical development.
Mr. Guerin has extensive experience and a successful track record in managing financial operations within biopharma companies. In 2013, he joined Onconova Therapeutics, now known as Traws Pharma, Inc. (Nasdaq: TRAW), to augment the company’s financial reporting, forecasting, and internal controls following its IPO in July 2013, and was named its CFO in 2016. During his tenure as CFO, Onconova completed several critical financing transactions, including a rights offering, public offerings, registered direct offerings, and at-the-market offerings. Onconova merged with Trawsfynydd Therapeutics, Inc. in April 2024, with concurrent investments from OrbiMed and Torrey Pines, to form Traws Pharma, Inc. and to advance product candidates of both companies in virology and oncology. The company also completed an additional
Prior to joining Onconova, Mr. Guerin worked as an interim senior finance and accounting executive, facilitating post-acquisition integration activities of newly acquired private equity portfolio companies. He also served as Vice President of Finance and CFO at Cardiokine, Inc., overseeing its New Drug Application filing and subsequent sale of the company. Earlier in his career, Mr. Guerin was Director, Financial Reporting and Internal Controls at Barrier Therapeutics, Inc., supporting the company through its IPO and follow-on offering.
Mr. Guerin began his career at Coopers & Lybrand in Philadelphia. He has a bachelor’s degree in accounting from DeSales University and holds CPA, CMA, and CFM professional certifications.
“I am very excited to join the Annovis team at this critical juncture for the company and for patients with neurodegenerative diseases, as buntanetap has demonstrated efficacy in smaller trials and is on track to replicate that success in larger, registrational clinical studies,” commented Mark Guerin, CFO at Annovis. “I look forward to supporting the clinical success of buntanetap and to Annovis delivering a therapeutic solution for patients who need it most.”
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.
Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com
FAQ
Who is the new CFO of Annovis Bio (NYSE: ANVS)?
What is Annovis Bio's main drug candidate?
What experience does Mark Guerin bring to Annovis Bio?
Why is this CFO appointment significant for Annovis Bio (ANVS)?
What diseases is Annovis Bio targeting with its drug development?
